Traditional medicines prescribed for prevention of <scp>COVID</scp>‐19: Use with caution

Parthasarathy, R.; Mathew, Milly; Koshy, Priyanka; Babu, M. Suresh; Abraham, Georgi

doi:10.1111/nep.13947

Cited by 7 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there may be many more such episodes that were not diagnosed and reported in COVID-19 infected patients. [ 20 ] As there is a scarcity of information on AKI in COVID-19 patients in India, this retrospective study was undertaken in a tertiary healthcare private facility, looking at the diagnosis and management of AKI during the first wave and part second wave COVID-19. A 6.8% prevalence of AKI was reported in our study of patients hospitalized with COVID-19.…”

Section: Discussionmentioning

confidence: 99%

Correlation of AKI with risk factors, ventilatory support, renal replacement therapy in a cohort of COVID-19 patients

Abraham¹,

MOGGA²,

Venkatraman³

et al. 2022

Indian J Nephrol

Self Cite

View full text Add to dashboard Cite

Introduction: There is a scarcity of information on the incidence and outcomes of acute kidney injury (AKI) in COVID-19 patients in India. Therefore, we analyzed the correlation of AKI risk factors, ventilatory support, and renal replacement therapy and compared the outcomes of first and second COVID-19 waves in this tertiary care center. Methods: We retrospectively analyzed the patients' medical records with a positive RT-PCR for COVID-19 between July 2020 and May 2021. We looked at the clinical outcomes of the first and second COVID-19 waves and documented the frequency, risk factors for AKI, and the relationship between AKI and in-hospital mortality. Univariate and multivariate binomial logistic regression yielded odds ratios for the risk variables of AKI. Risk differences and age-adjusted odds ratios, as well as 99.5% confidence intervals, were used to compare COVID-19 outcomes between the first and second waves. Results: Of the 1260 hospitalized patients with COVID-19, 86 (6.8%) presented with AKI and 8 (0.7%) patients required dialysis. The most common comorbidity was diabetes mellitus (55.2%), hypertension (42.1%), hypothyroidism (11.3%), and coronary artery disease (8.1%). A total of 229 (18.17%) patients were admitted to ICU, 574 (45.5%) received ventilation, and 26 (2.0%) required mechanical ventilation.The incidence of in-hospital death in the patients with AKI as per the stage from 1 to 3 was 9 (15.8%), 7 (35%), and 5 (55.6%), respectively.Compared to the first wave, the second wave cohort had a lower risk of AKI (adj OR: 0.426; CI: 0.232–0.782) and mortality (adj OR: 0.252; CI: 0.090–0.707). Conclusions: In our study, AKI prevalence was 6.8%, the need for ventilation was 45.5%, ECMO 0.2%, and the mortality rate 2.9%. Second wave of COVID-19 exhibits improved clinical outcomes compared to the first wave.

show abstract

Section: Discussionmentioning

confidence: 99%

Correlation of AKI with risk factors, ventilatory support, renal replacement therapy in a cohort of COVID-19 patients

Abraham¹,

MOGGA²,

Venkatraman³

et al. 2022

Indian J Nephrol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Among the available literature it was found that usage of Indian systems of Medicine like Siddha medicine would be a suitable candidate for patients with severe vaccine allergy as well as patients who are waiting to receive the first or second dose of COVID -19 vaccinations. Among the available Siddha polyhedral drugs, two important preparations namely Nilavembu kudineer and Kabha sura kudineer showed highly positive effects in decreasing the illness of COVID-19 in mild to moderate symptomatic patients [11][12][13][14][15]. In India, above Siddha medicines have been used to treat the dengue and chikungunya virus outbreak and found successful in treating the same [16].…”

Section: Introductionmentioning

confidence: 99%

An Alternate Approach in the Management of COVID – 19 in Unvaccinated / Vaccine Allergic Population – A Case Study

Bari

Sivashankar

2021

JPRI

View full text Add to dashboard Cite

The COVID-19 vaccines offer protection against the severe acute respiratory syndrome Corona virus 2 (SARS-CoV-2) by developing an immune response to the same. Further, there are mass vaccination programs being conducted across the globe. India administered COVID – 19 vaccines for more than 90 crores of people as on October 2021. However, there are still a bunch of people yet to receive vaccination. Adding to this, very few are found to be allergic to COVID – 19 vaccines. Hence there is a need for an alternative approach till the whole population of the world gets vaccinated. One such approach is prescribing Nilavembu kudineer and Kabha sura kudineer, a polyherbal Siddha medicine formulation of Traditional Indian system of Medicine. This case study highlights the positive effects and importance of the above mentioned polyherbal formulations in the management of mild to moderate COVID-19 patients. Hence, the same can be advised to the individuals who are yet to receive COVID-19 vaccine and persons who are allergic to COVID -19 vaccines.

show abstract

Rejuvenation of Traditional Medicine in the Twenty-First Century against SARS-CoV-2

Modanwal,

Mishra

2023

Ethnopharmacology and Drug Discovery for COVID-19: Anti-Sars-CoV-2 Agents From Herbal Medicines and Natural Products

View full text Add to dashboard Cite

Traditional medicines prescribed for prevention of COVID‐19: Use with caution

Cited by 7 publications

References 10 publications

Correlation of AKI with risk factors, ventilatory support, renal replacement therapy in a cohort of COVID-19 patients

Correlation of AKI with risk factors, ventilatory support, renal replacement therapy in a cohort of COVID-19 patients

An Alternate Approach in the Management of COVID – 19 in Unvaccinated / Vaccine Allergic Population – A Case Study

Rejuvenation of Traditional Medicine in the Twenty-First Century against SARS-CoV-2

Contact Info

Product

Resources

About